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Abstract: Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that can cause a
debilitating disease that is primarily characterized by persistent joint pain. CHIKV has been emerging
globally, while neither a vaccine nor antiviral medication is available. The anti-parasitic drug suramin
was previously shown to inhibit CHIKV replication. In this study we aimed to obtain more detailed
insight into its mechanism of action. We found that suramin interacts with virions and can inhibit
virus binding to cells. It also appeared to inhibit post-attachment steps of the infection process,
likely by preventing conformational changes of the envelope glycoproteins required for fusion and the
progression of infection. Suramin-resistant CHIKV strains were selected and genotyping and reverse
genetics experiments indicated that mutations in E2 were responsible for resistance. The substitutions
N5R and H18Q were reverse engineered in the E2 glycoprotein in order to understand their role in
resistance. The binding of suramin-resistant viruses with these two E2 mutations was inhibited by
suramin like that of wild-type virus, but they appeared to be able to overcome the post-attachment
inhibitory effect of suramin. Conversely, a virus with a G82R mutation in E2 (implicated in attenuation
of vaccine strain 181/25), which renders it dependent on the interaction with heparan sulfate for entry,
was more sensitive to suramin than wild-type virus. Using molecular modelling studies, we predicted
the potential suramin binding sites on the mature spikes of the chikungunya virion. We conclude
that suramin interferes with CHIKV entry by interacting with the E2 envelope protein, which inhibits
attachment and also interferes with conformational changes required for fusion.
Keywords: CHIKV; alphavirus; antiviral; suramin; E2 envelope protein; attachment; fusion;
drug repurposing
1. Introduction
Chikungunya virus (CHIKV) is a re-emerging alphavirus that is transmitted by Aedes sp.
mosquitoes and has caused several large outbreaks in the past 15 years. Before 2013 CHIKV was
circulating mainly in Africa and Asia [1], but following its introduction into the Caribbean it has now
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become endemic in Latin America as well [2]. Acute CHIKV infection is associated with fever, rash,
muscle pain, and general malaise. Furthermore, the virus often causes a debilitating joint pain that
can last for months to years [3]. Prophylactic or therapeutic treatment for CHIKV infections is still
not available on the market, and vector control measures do not provide the ultimate solution [4].
Although progress is being made in CHIKV vaccine and antiviral drug development [3,5–7], we would
still be poorly prepared in the face of a new CHIKV epidemic.
We and others have previously shown that the antiparasitic drug suramin inhibits CHIKV
replication by targeting an early step in the viral replication cycle [8–10]. Moreover, the compound also
inhibits CHIKV replication in a mouse model [11]. These findings show the potential for the (off-label)
therapeutic use of suramin for the treatment of chronic chikungunya fever, and possibly also for its
prophylactic use during severe CHIKV outbreaks.
CHIKV has a 11.8-kb single-stranded (ss) RNA genome of positive polarity, which is capped,
poly-adenylated and packaged into an icosahedral nucleocapsid that is surrounded by an envelope
containing 80 projections (spikes), each consisting of three E1-E2 (envelope proteins) heterodimers [12].
The E2 protein is involved in the interaction with the host cell and therefore is an important determinant
of pathogenicity, cellular tropism [13,14], and immunogenicity [15,16]. The viral replication cycle begins
with attachment of the virion to the cell surface through interactions with glycosaminoglycans, such as
heparan sulfate [17]. Subsequent binding to a receptor, like the recently identified Mxra8 protein [18]
will lead to uptake of the virion via receptor-mediated endocytosis [19]. Endosomal acidification causes
structural rearrangements in the virion that induce E1 protein-mediated fusion of the viral envelope
with the endosomal membrane [20]. This leads to nucleocapsid release and its disassembly in the
cytoplasm to liberate the RNA genome. Subsequently, the genome is translated into a polyprotein that
is processed into the non-structural proteins nsP1 to 4 that (together with host factors) assemble into
membrane-associated replication and transcription complexes (RTCs). The structural proteins (capsid,
E3, E2, 6k/TF and E1) are expressed from a subgenomic RNA in the form of a second polyprotein.
After autoproteolytic release of the capsid protein, the remainder of the structural polyprotein traffics
through the secretory pathway, during which it is cleaved by host cell proteases and undergoes
post-translational modifications like glycosylation. Ultimately, the mature envelope proteins will reach
the plasma membrane. Here, interaction between nucleocapsids and the cytoplasmic sides of the
envelope proteins are essential for the budding process and the formation of new virus particles [21].
The work presented here provides insight into the mode-of-action of suramin, through specific
analysis of virus binding and fusion, and by selecting and characterizing suramin-resistant CHIKV
variants, which contained N5R and H18Q mutations in the envelope protein E2. Moreover, we found
that a virus with the G82R mutation in E2, which renders the virus dependent on heparan sulfate
binding for infectivity and was implicated in attenuation of vaccine strain 181/25 [13], was more sensitive
to suramin than wild-type CHIKV. Molecular docking studies provided more insight into suramin’s
inhibitory activity, since the compound was predicted to bind to virus particles at positions that could
interfere with conformational changes in the envelope proteins that need to occur during entry.
2. Materials and Methods
2.1. Cells, Compounds, and Viruses
Vero E6 and BHK21 cells were grown in DMEM or BHK medium (G-MEM BHK-21 with
10% Tryptose phosphate broth and 10 mM HEPES), respectively, supplemented with 8% fetal calf
serum (FCS) and penicillin/streptomycin. BS-C-1 cells were cultured as previously described [22].
Suramin, chloroquine and ammonium chloride were purchased from Sigma and 3H-suramin from
Hartmann Analytic. CHIKV LS3 (KC149887) and Semliki Forest virus strain SFV4 (KP699763.1) were
launched from full-length cDNA clones. All studies with live CHIKV were performed in biosafety
cabinets in BSL-3 facilities.
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2.2. Preparation of 35S-labeled Viruses and Purification of Virus Stocks
35S-labeled CHIKV and SFV were produced in Vero E6 cells as described before [23]. To remove
non-incorporated labels, the cell culture supernatant was subjected to pelleting through a sucrose
cushion by ultracentrifugation in a SW41 Ti rotor (at ~200,000 g for 2 h). Virus pellets were resuspended
in 1xTESV buffer (20 mM Tris-HCl pH 7.4, 1 mM EDTA, 100 mM NaCl), before aliquoting and storage
at −80 ◦C.
2.3. Virus Attachment Assay
To study virus binding, 35S-CHIKV or 35S-SFV samples (1 × 104 counts per minute, CPM) were
incubated with Vero E6 cells for 1 h at 4 ◦C, in the presence or absence of suramin, followed by
washing and lysis in 4x dye-free Laemmli sample buffer (LSB). The amount of bound radioactivity in
samples was quantified by liquid scintillation counting with a Beckman-Coulter LS6500 Multi-Purpose
scintillation counter and Ultima Gold™ scintillation liquid. The binding of fluorescently labeled CHIKV
(DiD-CHIKV) to BS-C-1 cells was assessed by fluorescence microscopy, as previously described [22].
2.4. Bulk Fusion Assay
Pyrene-labelled CHIKV and liposomes containing phosphatidylcholine (PC),
phosphatidylethanolamine (PE), sphingomyelin and cholesterol in a molar ratio of 1:1:1:1.5
were used in a bulk fusion assay as previously described [19].
2.5. 3H-Suramin-Virus Binding Assay
Purified virus particles prepared in 1xTESV buffer (containing only trace amounts of protein from
the culture medium) were incubated with 0.5 × 106 CPM of 3H-suramin, for 1 h at 37 ◦C. The unbound
suramin was removed by gel-filtration using P30-Microbiospin columns (BioRad, Berkeley, CA, USA)
according to the manufacturer’s instructions; virions in the flow-through were lysed in dye-free LSB
and bound radioactive suramin was quantified by scintillation counting as described under Section 2.3.
2.6. Reverse Genetics
The mutations listed in Table 1 were introduced into the pMALS2L (G588A, A979G, G980A,
T5645C) and pMALS2R (A8554G, C8595A) plasmids [24] using QuickChange site-directed mutagenesis
(Stratagene, La Jolla, CA, USA). Subsequently, single or combined mutations were transferred
to the CHIKV LS3 plasmid by using unique BamHI, XmaI, AgeI, XhoI and SfiI restriction sites.
The reverse-engineered mutant CHIKV mutants were launched via in vitro transcription (AmpliScribe™
T7 High Yield Transcription Kit, Lucigen, Middleton, WI, USA) and RNA transfection of BHK-21 cells
as described previously [24]. After 24 to 48 h, when extensive cytopathic effects (CPE) had occurred,
the virus-containing supernatants were harvested and used to produce passage 1 virus stocks on Vero
E6 cells, which were used in subsequent experiments. These virus stocks were verified by Sanger
sequencing of the full genome to confirm the presence of the introduced mutations and absence of other
mutations. Only in the case of G980A (in nsP1) we observed rapid reversion to the wild-type genotype.
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Table 1. Mutations in CHIKV resulting from serial passaging in the presence of increasing (suboptimal)
concentrations of suramin.
Mutation in
At P5 (150 µM Suramin) At P7 (300 µM Suramin)
nt Substitution AA Substitution nt Substitution AA Substitution
nsP1 G588A R171Q
G588A
A979G
G980A
R171Q
T301K
G302R
nsP3 U5645C opal524R ∆U5645-A5650 ∆opal524L525
E2 A8554G N5R A8554GC8595A
N5R
H18Q
2.7. RNA Isolation and RT-qPCR
Total cellular RNA was isolated by lysing the cells in LiDS/LET as previously described [24] or
in TriPure reagent according to the manufacturer’s (Invitrogen, Waltham, MA, USA) instructions.
To measure genome copy numbers an internally controlled TaqMan quantitative RT-PCR assay was
used [24].
2.8. Cytopathic Effect (CPE) Reduction Assay
CPE reduction assays were basically performed as previously described [8] with some
modifications. VeroE6 cells were seeded in 96-well clusters at a density of 5000 cells/well the
day before infection. The following day, the medium was replaced with serial dilutions of suramin
in EMEM/2% FCS and cells were infected with CHIKV at an MOI of 0.05. The incubation period
was 72 h for CHIKV mutants S4.1, S4.3, S5 and 96 h for wt CHIKV and mutants S2.1, S2.3, S3, S7,
S8 and S9, or 120 h for mutants S2.2 and G82R. Suramin-treated uninfected cells were included as
controls to exclude potential cytotoxic/cytostatic effects of the compound treatment. After performing
a colorimetric viability assay with MTS reagent (Promega, Leiden, The Netherlands) for 2 h at 37 ◦C,
30 µl/well of 37% formaldehyde was added and absorption was measured at 450 nm using an EnVision
Multilabel Plate Reader (PerkinElmer, Waltham, MA, USA). The EC50, defined as the concentration
of suramin required to inhibit virus-induced CPE by 50% was determined by non-linear regression
analysis using GraphPad Prism v8.0.
2.9. Plaque Number Reduction Assay
To study virus entry, Vero E6 cells were incubated with approximately 100 plaque forming
units (PFU) of CHIKV for 1 h at 37 ◦C in the presence of a range of suramin concentrations.
After removing the inoculum, the cell monolayer was washed and overlay medium containing
1.2% Avicel RC-581 (FMC BioPolymer, Philadelphia, PA, USA) in DMEM, 2% FCS, 25 mM HEPES,
and penicillin/streptomycin was added. After three days, the cell monolayers were fixed with
3% formaldehyde in PBS solution and plaques were stained and counted. To study attachment,
suramin treatment and virus uptake were done for 1 h at 4 ◦C, and 1000 PFU were used in order to
detect approx. 100 plaques in the untreated wells, as low temperature diminished virus binding.
2.10. Molecular Modelling
Molecular Operating Environment (MOE) 2018.10 [25] and Maestro [26] software was used.
The CHIKV E2-E1 glycoprotein heterodimer (PDB ID 3N42) and trimeric complex (PDB ID 3J2W)
were preprocessed using the Schrödinger Protein Preparation Wizard by assigning bond orders,
adding hydrogens, and performing a restrained energy minimization of the added hydrogens using the
OPLS_2005 force field. The missing residues of E2 (1–6) were manually introduced and the downstream
docking processes are described in more detail in Appendix A. The electrostatic potential surface was
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obtained using the Surfaces and Maps tool in MOE after splitting the molecule in multiple chains.
Figures were prepared with MOE.
2.11. Statistics
GraphPad Prism 8 was used as previously described [8,23] for EC50 determination by non-linear
regression. The statistical analysis was performed with one-way ANOVA using Dunnett’s multiple
comparison test (Figure 1a–c).Viruses 2020, 12, x FOR PEER REVIEW 6 of 15 
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Figure 1. The effect of suramin on the early events of Chikungunya virus (CHIKV) infection (a) The
binding of 35S-labelled CHIKV (1 × 104 CPM) to Vero E6 cells in the presence or absence of suramin
was determined at 4 ◦C by scintillation counting of remaining radioactivity in cellular lysates obtained
after extensive washing (average +/− SD; n = 3). (b) Binding of fluorescently (DiD)-labeled CHIKV
to suramin-treated BS-C-1 cells, analyzed by fluorescent microscopy, in the presence of increasing
compound concentrations. (c) Fusion of pyrene-labeled CHIKV in a bulk fusion assay with liposomes,
triggered by lowering the pH, in the presence of increasing suramin concentrations (n = 5 and 3,
for untreated and treated samples, respectively). (d) Binding of 3H-labeled suramin (5 × 105 CPM) after
a 1-h incubation at 37 ◦C to CHIKV (purified virus was used to exclude interference by serum proteins).
The control used in this assay was culture medium from uninfected cells that was treated the same way
as when purifying virus (n = 3). The data represent the means ± the SD and significant differences are
indicated with * (**** p < 0.001, *** p < 0.005, ** p < 0.01, * p < 0.05 and ns as not significant).
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3. Results and Discussion
3.1. Suramin Inhibits Viral Attachment and Fusion by Interacting with the Chikungunya Virion
Several experiments were carried out to analyze the impact of suramin on the early events of
infection, i.e., virus attachment, internalization, and fusion. 35S- or DiD-labeled CHIKV [22] were
used in virus binding assays, in the presence or absence of suramin, at 4 ◦C. Active endocytosis
does not occur at temperatures below 18 ◦C [27] and therefore suramin was expected to remain in
the extracellular environment. Virus attachment to the cell surface probably involves electrostatic
interactions with the GAGs or other plasma membrane factors (receptors, adhesion molecules)
and infections can be synchronized by placing cells at 4 ◦C. By directly measuring the amount of
radioactively- or fluorescently-labeled virus in the presence of increasing concentrations of compound,
we found that suramin inhibited CHIKV attachment (Figure 1a,b) in two distinct cell lines and with
two different experimental readouts. Binding of 35S-labelled SFV was even more strongly inhibited by
suramin (supplemental Figure S1a), which is in line with suramin’s previously observed lower EC50
for SFV compared to CHIKV [8]. In addition, suramin (30 µM) completely inhibited pyrene-labeled
CHIKV from fusing with liposomal membranes at pH ~5.5 in the absence of host proteins, as shown
in Figure 1c [19]. Because suramin is known to bind to positive charges on the surface of proteins,
we suspect that suramin binds directly to the envelope proteins, thereby preventing the conformational
changes that are required for fusion. In contrast to Ho et al., who studied the effect of suramin on
surface-expressed envelope proteins in insect cells that were subsequently triggered to fuse at low pH,
we studied the effect of suramin on membrane fusion in the context of whole virions. The ~100-fold
lower EC50 in the fusion assay (Figure 1c) compared to the binding assay (Figure 1a) makes it tempting
to conclude that suramin inhibits fusion much more than binding, but these differences might very
well be due to the very different experimental setup of the (in vitro liposome-based) fusion and the
(cell-based) binding assay.
To confirm the interaction of suramin with virions, we incubated purified CHIKV (lacking serum
proteins as these are known to strongly bind suramin; [28]) with 3H-labeled suramin. Compared to a
control supernatant from mock-infected cells (which bound 3000 CPM of suramin) purified CHIKV
bound over 30,000 CPM of 3H-suramin (Figure 1d), confirming that the compound did interact with
virus particles. 3H-suramin also interacted with SFV (Figure S1c), and more specifically with the (native)
E proteins on the surface of intact virions, since treatment with proteinase K or heat denaturation
severely decreased the quantity of bound radiolabeled suramin. For other viruses like enterovirus A71
(EV-A71) and human immunodeficiency virus 1 (HIV-1) it was also found that suramin blocked their
access to cellular receptors by directly interacting with virions [29,30].
Surprisingly, when SFV particles were pre-attached to cells (at 4 ◦C, in the absence of compound)
and treated with suramin at 37 ◦C, only a minor non-significant inhibition of virus uptake was observed,
even at high suramin concentrations (Figure S1b). Hence it is possible that at physiological temperature,
pre-attached viruses cannot be displaced from their receptors by the compound, implying that the
receptor- and suramin-binding sites overlap or the entry process might be too fast to be inhibited by
suramin. When evaluating these direct binding studies, it should be noted that it remains unclear what
fraction of the bound virions will actually lead to a productive infection.
The inhibitory effect of suramin on the binding of virus particles to the cell surface could be due
to its direct interaction with virions and/or with cellular receptors. The direct binding assays with
radiolabeled or fluorescently labeled viral particles clearly showed that suramin inhibits binding/fusion
of both CHIKV and SFV (Figure 1 and Figure S1). This is in contrast with our earlier study [8], in which
we concluded that suramin inhibits an early step, but not attachment. In that study, we relied on an
RT-qPCR assay to quantify cell-bound CHIKV. However, this is an indirect measurement and the
majority of the detected RNA molecules do not represent infectious particles, as we and others found
that genome copy to PFU ratios of commonly used virus stocks were generally over 1000:1 [31,32].
At least in part, this is due to the fact that virus stocks are generally harvested when extensive
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cytopathic effect (CPE) has occurred, which leads to the release of viral RNA not associated with
infectious virus particles, e.g., in the form of naked RNA, nucleoprotein complexes or nucleocapsids.
Therefore, we no longer consider RT-qPCR an appropriate assay to study CHIKV binding when
standard, non-purified CHIKV specimens are used.
To evaluate whether the effect of suramin on CHIKV binding could be reliably measured by an
improved RT-qPCR-based assay, we have used a PEG-precipitated virus stock to improve the CHIKV
RNA to PFU ratio. After titration on Vero E6 cells, the ratio ranged from 7632:1 in the non-purified stock
to 68:1 in the PEG-precipitated stock. Clearly, even after this procedure, the number of CHIKV RNA
molecules still strongly outnumbers the number of infectious particles. Subsequently, we repeated the
qPCR-based measurement of virus binding at 4 ◦C in the presence and absence of suramin (Figure S2),
for both non-purified and PEG-precipitated virus stocks. While for the former there was an unexpected
increase in detected CHIKV RNA in the presence of suramin, the PEG-precipitated stock showed a
slight decrease, confirming that the quality of the virus stock strongly influences the experimental
outcome and conclusions.
3.2. Suramin-Resistant CHIKV Variants Acquired Mutations in the Envelope Protein E2
Repeated passaging of CHIKV in the presence of increasing suramin concentrations that do not
fully inhibit replication (from 25 up to 300 µM) yielded variants that could grow to titers above 105
PFU/mL in the presence of 150 µM suramin. By passage 5 (P5) and passage 7, drug concentrations of
150 and 300 µM, respectively, were tolerated, concentrations that reduced wild-type virus titers by at
least 2 logs [8]. Genotyping of the P5 virus revealed the presence of three nonsynonymous mutations
in the CHIKV nsP1, nsP3 and E2 proteins. Two passages later (P7), the suramin-resistant variant had
acquired several additional mutations in the same 3 proteins (Table 1).
To pinpoint which of these mutations is/are responsible for the suramin-resistant phenotype,
they were all reverse engineered into our CHIKV full-length cDNA clone [24], either alone or in
combination. For each of the reverse-engineered viruses, the plaque phenotype and sensitivity to
suramin were determined and for several mutants the growth kinetics were also compared.
Viruses with the R171Q and opal524R mutations (CHIKV mutants S4.1, S4.3 and S5) were found
to produce larger plaques on Vero E6 cells, suggesting they could be linked to cell culture adaptation.
Both R171Q and opal524R had been previously reported in CHIKV isolates such as MADOPY1, StBI and
StVE (GenBank accession numbers KP003808.1, KP003811.1, and KP003810.1 respectively) which all
had been passaged in cell culture prior to sequencing [33]. The mutation opal524R in the nsP3-coding
region was reported also by Mounce et al. in the context of resistance selection against the compound
DFMO [34], alongside with other nsP mutations. In the case of CHIKV and other alphaviruses (SFV,
ONNV), evolutionary pressures have maintained both variants (stop and arginine codon) as it offers a
fitness advantage when switching between vertebrate and invertebrate hosts [35–37]. The combination
of the R171Q and opal524R mutations was also found independently during the selection of CHIKV
variants that were resistant to an unrelated compound [38], and they merely appear to reflect adaptation
to repeated passaging in mammalian cells (under stress).
In contrast, the T301K mutation in nsP1, causing a small-plaque phenotype, and the two mutations
in E2 (N5R and H18Q) that did not alter the plaque phenotype (Figure 2a), have to our knowledge not
been previously identified in other isolates. However, the T301 residue was found to be changed to
an I in the CHIKV 181/25 vaccine strain, that was attenuated by repeated passaging in MRC-5 cells,
and was accompanied by mutations T12I and G82R in E2, C42F in 6K and A404V in E1 [39]. It was
later proven that T301I was not related to the attenuated phenotype of the vaccine strain, but that the
two E2 mutations were responsible [40].
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Figure 2. Characterization and suramin sensitivity of reverse engineered CHIKV variants (a) Mutations
identified in suramin-resistant CHIKV mutants (Table 1) were reverse-engineered (individually or in
combinations) into infectious cDNA clone CHIKV LS3. Plaque morphology (in the absence of suramin)
and EC50 (mean, n = 8) for suramin as determined by CPE reduction assay (curves in graph above table)
are shown for each of the recombinant viruses. The values were determined from two independent
experiments performed in quadruplicate. (b,c) Replication kinetics of CHIKV mutants S4, S5, S9 and
wt virus were compared during infection of Vero E6 cells in the absence (b) or presence of 0.2 mM
suramin (c). At several time-points p.i., culture supernatants were harvested and infectious virus titers
were determined by plaque assay (n = 2). (d) Side-by-side comparison of the 36 h p.i. titers of various
mutants and wt virus grown in the absence (N.T., not treated) or presence of 0.2 mM suramin (n = 2).
All experiments were performed in Vero E6 cells and the data represent mean ± the SD.
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Reverse engineering of the N5R and H18Q mutations in E2 produced CHIKV variants with
an increased tolerance to suramin (Figure 2a), as an increase in EC50 was observed when both
mutations were present (S5 and S9 in Figure 2a). This suggested that the two E2 mutations cause the
suramin-resistant phenotype, identifying E2 as the target of the compound. The N5R mutation alone
(S7) already provided suramin resistance, while H18Q (which appeared later in resistance selection)
on its own (S8) had a less pronounced effect on resistance. However, as discussed below (Figure 3a),
in another more direct assay there is a cumulative positive effect when the H18Q mutation is introduced
in a virus that already contains the N5R mutation (S9).
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Figure 3. The effect of E2 mutations on suramin-resistance and the early steps of infection (a) Virus
uptake and infectivity were determined based on a PRNT-like assay. Approx. 100 PFU of wt CHIKV
and mutants S7, S8, S9 and G82R were incubated with Vero E6 cells for 1h in the presence or absence
of increasing suramin concentrations. Afterwards the inoculum was removed, the monolayers were
washed with PBS and overlay medium was added. After a three-day incubation, the cells were fixed
and plaques were stained and counted. (b) The plaque number reduction assay was used to analyze
synchronized attachment of wt CHIKV and variant S9 at 4 ◦C, in the presence and absence of suramin.
After binding for 1 h in the cold, the inoculum and suramin were removed and replaced with overlay
medium without suramin, and the rest of the procedure was performed as described under (a). The data
represent the means ± the SD (n = 3).
The replication kinetics of relevant mutants, S4.3 (containing mutations in nsPs only), S9 (containing
only the E2 mutations), and S5 (containing all mutations) were slightly faster than that of the wt control,
reaching slightly higher titers by 24 h p.i., but similar titers by 36 h p.i. (Figure 2b). Despite its faster
replication, S4 is as sensitive to suramin treatment as the wt virus, with a 3-log reduction in titers
upon treatment with 200 µM suramin. The S9 and S5 mutants, on the other hand, exhibited a titer
reduction of only 1 log (Figure 2c,d). These findings indicate that the nsP mutations (the S4 variant)
were not involved in suramin resistance and that the E2 mutations alone were responsible for the
resistant phenotype.
3.3. The N5R and H18Q Mutations in E2 Enhance CHIKV Entry
To understand how the E2 mutations affect CHIKV infectivity in the presence of suramin,
we analyzed the early steps (attachment, uptake, fusion) of infection, using a plaque number reduction
assay in which virus and compound were present only during the first hour. We also reverse engineered
a virus with a G82R mutation in E2, as this mutation was previously shown to render CHIKV fully
dependent on HS binding for infection and is responsible for the attenuated phenotype of CHIKV
vaccine strain 181/25 [13,41]. Among all E2 mutant viruses tested, the G82R mutant was extremely
sensitive to suramin, as its uptake and infectivity were almost abolished in the presence of 50 µM
suramin, whereas this concentration merely caused a 40% reduction for wt virus (Figure 3a). The S7
and S9 mutants were indeed more resistant to suramin than wt virus, as their entry was not significantly
inhibited by the presence of 50 µM suramin, while that of wt and S8 was. In the presence of 200 µM
suramin, the uptake of wt virus, mutant S7 and mutant S8 was reduced to 40% of that of untreated cells,
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while the uptake of mutant S9 remained at ~60%, confirming that the presence of both E2 mutations
leads to an increased resistance. The binding of mutant S9 at 4 ◦C, however, was inhibited to the
same extent by suramin as that of wt virus, suggesting the N5R and H18Q mutations do not offer
resistance to the compound during the attachment step (Figure 3b). This finding was corroborated by
a time-of-addition assay where the pre-treatment of cells with suramin inhibited wt and mutant S9 to
the same extent. However, if treatment was started at the moment of infection or later, the S9 mutant
replicated better than the wt virus (supplemental Figure S3). Therefore, it seems that the two mutations
allow the virus to overcome the inhibitory effect of suramin at a post-attachment step, such as fusion.
3.4. Molecular Modelling Predicts Suramin to Bind between Two Adjacent E2 Proteins in a Mature Spike
The observations on the involvement of E2 mutations in suramin resistance prompted us to
explore the interaction between the viral envelope protein and compound in more detail, by using a
molecular docking approach. We employed a molecular docking approach using suramin and the
E2 protein structure on its own, in the form of the E1-E2 heterodimer or as present within a mature
CHIKV spike. Our initial attempts of docking suramin to an isolated E2 protein structure or to the
E1-E2 heterodimer (PDB ID 3N42) revealed that the compound could interact with a region lacking a
clear secondary structure (a groove between domains A and C and linked to the flexible N-terminal
part of E2). The N5R mutation that was implicated in suramin resistance maps to this flexible region in
the N-terminal domain of E2. Based on this predicted binding, the introduction of negative charges at
position 6 and 160 (F6D, T160D) were expected to repel the binding of suramin to that area. To test
whether this was indeed the case, these mutations were reverse engineered. The recombinant viruses
had a plaque size similar to the wt CHIKV, but in CPE reduction assays they were more or equally
sensitive to suramin, with EC50 of 54.5 µM (for F6D) and 16.7 µM (for T160D), compared to 55.5 µM of
wt CHIKV. Previously Ho et al. have also docked suramin to the E1-E2 heterodimer and predicted that
suramin would bind in a region between the two proteins [9].
In a more recent publication, a structure for the mature CHIKV spike was obtained by modeling
the crystal structures of the E1 and E2 proteins into the cryo-EM image of a CHIKV VLP [42]. Due to
this novel information, we now consider the earlier docking studies to be less representative for the
natural situation, since in the context of a virion the suggested suramin binding sites would not be
exposed in mature spikes, which are formed by E1-E2 heterotrimers (See supplemental Figure S4).
Therefore, to refine our understanding of the possible electrostatic interactions between suramin and
the surface of CHIKV, we employed a molecular docking approach based on the more relevant model
of the envelope heterotrimer.
In this model, suramin (depicted in yellow) interacts (∆G −96.97 kcal/mol) with a very flexible
loop in the N-terminal region of one E2 molecule, while it extends towards the middle of domain A
of an adjacent E2 (Figure 4a). Moreover, several suramin molecules are predicted to bind the same
spike. Because domain A is involved in receptor recognition, as well as being the target of neutralizing
antibodies, it has a pivotal role in the viral replicative cycle [14,16,18,43].
By analyzing the charge distribution on the surface of the CHIKV spike, it became clear that the
N-terminal loop of E2 harbors positive charges (K at positions 3 and 10). By acquiring the mutation
N5R, there was a clear increase in the positive charges (differences indicated with black rectangles in
Figure 4b,c), probably leading to a stronger interaction with suramin and perhaps pulling it away from
another area of the spike. Counterintuitively, because one would expect that a resistance mutation
would prevent the interaction with suramin, we speculate that the N5R mutation actually attracts the
compound thereby changing the binding mode. Perhaps the N5R mutation directs suramin away from
the center of domain A, which is known to be involved in receptor recognition and is also the target of
neutralizing antibodies [15,18].
According to our molecular modelling prediction, the H18Q mutation, which is located in a region
across from the E1 fusion loop, might enhance the effect of the N5R mutation by stabilizing the flexible
N-terminal loop to achieve a better interaction with the compound or could cause some other structural
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changes in the heterotrimer leading to a decreased affinity for suramin. Additionally, H18Q could
also facilitate fusion by aiding in the conformational rearrangements required for exposure of the
fusion loop. Combined, the N5R and H18Q mutations might change the binding geometry of
suramin, perhaps sidetracking it from the core of the E1/E2 heterodimer/spike and/or facilitating fusion
(Figure 4c).
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Figure 4. Molecular docking of suramin to a mature CHIKV spike (a) The top view of a full wt E1-E2
heterotrimer (PDB ID 3J2W). The E2 proteins are represented as blue ribbon, the E1 as purple ribbon and
the fusion loop as orange ribbon; the N5 and H18 residues are represented with carbon atoms in blue
and green, respectively, and residue G82 with carbon atoms in red, belong to E2. Suramin is represented
in yellow (3 molecules, carbon atoms and molecular surface). The inset (black rectangle) shows a
clearer magnified view of the spike core and the positioning of suramin with respect to the residues N5,
H18 and G82. (b) Electrostatic potential (Coulombic surface coloring) of the heterotrimer of wt CHIKV.
The black rectangle marks the N-terminal domain of one E2 protein, where the positive charges are
found. (c) Electrostatic potential (Coulombic surface coloring) of the heterotrimer of the N5R/H18Q
mutant, CHIKV S9. The black rectangle highlights the N-terminal domain of E2 showing an increase
in positive charges (blue molecular surface). For presentation purposes, the transmembrane and
C-terminal segments of the E1 and E2, which interact with capsid proteins seen in (a), were removed.
Our hypothesis that suramin is attracted to the center of domain A is further supported by the
observation that the CHIKV variant that is completely dependent on heparan sulfate interactions for
infectivity [13,41] has a G82R mutation in E2. In CPE-based assays, the G82R mutant is more sensitive
to suramin than wt CHIKV, since 15 µM suramin still gave 85% protection, resulting in an EC50
15 µM for suramin, while the G82R mutation did not influence the EC50 for the unrelated compound
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6-aza-uridine. Interestingly, residue G82 is located at the center of the spike, where the A domains of
the three E2 subunits are found (highlighted in red in Figure 4a), and maps to the area that interacts
with Mxra8, a receptor which was recently found to promote CHIKV entry [18]. The introduction of a
positive charge at position 82 of E2 could increase the affinity for suramin at the center of the spike and
block cell attachment.
These results suggest that suramin could have more impact on the infection when it is attracted to
the center of the spike, while more distant positive charges could direct it away from this important
region, allowing attachment and interaction with specific receptors, which could explain why the
observed the suramin-resistance mutations emerged.
4. Conclusions
The aim of our study was to understand how suramin inhibits the early steps of the replicative
cycle of CHIKV and other alphaviruses. We have shown that suramin can interact with CHIKV
in vitro, and inhibits attachment of the virus to the host cell. Moreover, it could prevent conformational
rearrangements in the viral spike glycoproteins that are required for fusion. We were able to select
suramin-resistant CHIKV variants and demonstrated that the N5R and H18Q mutations in E2 were
responsible for resistance. These mutations did not offer the virus a major advantage during the
binding to cells in the presence of suramin. The benefit of these mutations appears to play a
role in overcoming suramin’s inhibitory effects during later stages of entry, perhaps allowing the
suramin-bound (mutant) spikes to undergo conformational changes required for fusion and progression
of the infection. Although CHIKV is able to acquire resistance mutations to the compound, suramin is
still an interesting drug candidate as the level of resistance is rather low and required repeated passaging.
Additionally, suramin protected human primary dermal fibroblasts from CHIKV-induced CPE with
an EC50 of approx. 95 µM, proving its efficacy in a more relevant cell model for arbovirus infection.
Regarding its use in humans, suramin could be explored as prophylactic in the context of an
outbreak, since it is a compound with one of the longest known half-lives in humans [44]. In previous
clinical studies, concerning the treatment of AIDS and certain types of cancer, multiple and serious
side effects were attributed to the long-term use of suramin [45]. However, this concerned seriously ill
patients and long-term treatment. Such an extended regimen is not required for the treatment of parasitic
infections for which suramin has proven to be effective and much better tolerated. Therefore, we believe
that also for the short-term treatment or prevention of chikungunya virus infections, suramin would
be an interesting drug to evaluate.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/12/3/314/s1,
Figure S1: Effect of suramin on the early events of SFV infection, Figure S2: Effect of suramin on CHIKV
uptake analyzed by RT-qPCR and Figure S3: The effect of E2 mutations on suramin-resistance determined
through a time-of addition assay. Figure S4. Location of F6 and T160 in E2 with respect to a bound molecule of
suramin (yellow).
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Appendix A
Molecular Modeling—In Depth Description of Molecular Modelling
All molecular docking studies were performed on a Viglen Genie Intel®CoreTM i7-3770 vPro
CPU@ 3.40 GHz × 8 running Ubuntu 14.04. Molecular Operating Environment (MOE) 2018.10
(Chemical Computing Group, 2018) and Maestro (Schrödinger, 2017) were used as molecular
modelling software. The CHIKV E2-E1 glycoprotein heterodimer and trimeric complex structures were
downloaded from the PDB data bank (http://www.rcsb.org/; PDB code 3N42 and 3J2W). The proteins
were preprocessed using the Schrödinger Protein Preparation Wizard by assigning bond orders,
adding hydrogens and performing a restrained energy minimization of the added hydrogens using
the OPLS_2005 force field. The missing N-terminal residues at the start of the E2 protein (residues 1–6)
were manually introduced and energy minimized. Suramin structure was built with MOE and then
prepared using the Maestro LigPrep tool by energy minimizing the structures (OPLS_2005 force
filed), generating possible ionization states at pH 7 ± 2, generating tautomers and low-energy ring
conformers. SiteMap tool in Maestro was used to individuate a potential binding area in proximity of
the important mutations, N5R and H18Q. The selected area was used as binding site for the molecular
docking studies. For the trimeric complex, three different, one for each heterodimer, 36 Å docking grids
(inner-box 10 Å and outer-box 46 Å) were prepared using as centroid a threonine residue localized
at the spatial center between the N5 and H18 of two adjacent E2 subunits (Figure A1). In the case of
the isolated E2 unit, the same binding area for grid generation was defined selecting as centroid a
dummy atom, manually positioned at equal distance from N5 and H18. Molecular docking studies
were performed using Glide SP precision keeping the default parameters and setting 5 as number of
output poses per input ligand to include in the solution. The output database was saved as mol2 file.
The docking results were visually inspected for their ability to bind the active site. The electrostatic
potential surface was obtained using the Surfaces and Maps toll in MOE after splitting the molecule in
multiple chains. Figures were prepared with MOE.
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